Skip to content

Clinical proof-of-concept of millisecond dose delivery potential in moving targets.

Clinical proof-of-concept of millisecond dose delivery potential in moving targets. - FLASH Beyond Doubt

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON57588
Enrollment
40
Registered
2025-06-02
Start date
2025-08-10
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer lung carcinoma

Interventions

None listed

Sponsors

HollandPTC
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - > 18 years old at the time of signing informed consent - Patients receiving curative intent proton therapy for lung cancer - Ability to understand the requirements of the study and to give written informed consent, as determined by the treating physician - Written Informed consent obtained

Exclusion criteria

Exclusion criteria: - Pacemaker or ICD - Pregnant

Design outcomes

Primary

MeasureTime frame
The endpoints of the study are divided in the endpoint for the first and the second part of the study: Part I Quantification of the accuracy of phase matching, expressed in the resemblance between the kV-images and the Digitally Reconstructed Radiographs (DRRs) of the individual phases of the 4DCT. Part II The alignment between the kV-image, used as a surrogate for the FLASH beam, and the DRR of the predetermined phase of the 4DCT. The study procedures are further explained in the protocol section 5.2.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)